NCT03158064 2026-01-28
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT00453310 2015-10-27
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00042952 2013-01-17
Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Terminated